KPC Pharmaceuticals (SHSE:600422) ROCE %: -6.58% (As of Mar. 2026)

What is KPC Pharmaceuticals ROCE %?

KPC Pharmaceuticals SHSE:600422 +4.55% 62 ROCE % is -6.58% as of Mar. 2026. GuruFocus rates SHSE:600422 with a GF Score™ of 62/100 and a GF Value™ of ¥11.77 (Significantly Undervalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. KPC Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -6.58%.

KPC Pharmaceuticals (SHSE:600422) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

KPC Pharmaceuticals ROCE % Related Terms

KPC Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for KPC Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KPC Pharmaceuticals ROCE % Chart

KPC Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

12.70

9.46

11.56

12.36

6.96

KPC Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															8.64	8.31	4.71	5.33	-6.58

62GF Score

KPC Pharmaceuticals Inc SHSE:600422

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

KPC Pharmaceuticals ROCE % Calculation

KPC Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	524.146	/	( ( (12611.367 - 5490.859)	+	(11773.564 - 3825.689) )	/ 2 )
	=	524.146	/	( (7120.508	+	7947.875)	/ 2 )
	=	524.146	/	7534.1915
	=	6.96 %

KPC Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-518.512	/	( ( (11773.564 - 3825.689)	+	(11215.403 - 3411.923) )	/ 2 )
	=	-518.512	/	( ( 7947.875	+	7803.48 )	/ 2 )
	=	-518.512	/	7875.6775
	=	-6.58 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -6.58% mean?

KPC Pharmaceuticals (SHSE:600422) has a ROCE % of -6.58% as of Mar. 2026.

Is KPC Pharmaceuticals' ROCE % too high?

KPC Pharmaceuticals' current ROCE % is -6.58%. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does KPC Pharmaceuticals' ROCE % compare to ZTS and UTHR?

KPC Pharmaceuticals' ROCE % of -6.58% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KPC Pharmaceuticals's current ROCE % is -6.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is KPC Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.77, compared to a current price of ¥8.05 — trading 31.6% below its estimated fair value. The current ROCE % is -6.58%. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current ROCE % is -6.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?

Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued. The current stock price of ¥8.05 is trading 31.6% below its estimated GF Value™ of ¥11.77. GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for SHSE:600422:

ROCE %: -6.58%
GF Value™: ¥11.77 vs. price of ¥8.05 (31.6% below fair value)
GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KPC Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SHSE:688799 SHSE:688621 SZSE:000597 SHSE:603367 SHSE:600252 SHSE:688276 SZSE:301393 SZSE:301201 SHSE:600195 SZSE:002424 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106

Website http://www.kpc.com.cn

KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.

62GF Score

Get the complete analysis for SHSE:600422

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.05

Price

¥11.77

GF Value

View SHSE:600422 Analysis

See ROCE % data for all stocks →